Sonoma Pharmaceuticals share price logo

Sonoma Pharmaceuticals

NASDAQ: SNOA

$1.27

+0.02

(+2.01%)

as on

Sonoma Pharmaceuticals Stock Performance

as on September 26, 2026 at 2:15 pm IST

  • Day's Low

    Day's High

    $1.24
    $1.29
    downward going graph

    2.36%

    Downside

    1.57%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $0.85
    $4.60
    downward going graph

    33.06%

    Downside

    262.20%

    Upside

    downward going graph

Sonoma Pharmaceuticals share price movements today

Previous Close
$1.25
Open
$1.24
Volume
175.2K
Market Cap
$6.0M
Day's Low - High
$1.24 - $1.29
52 Week Low - High
$0.85 - $4.60

Sonoma Pharmaceuticals Historical Returns

1 Month Return
-7.97 %
3 Month Return
+ 13.39 %
1 Year Return
-68.56 %
3 Year Return
-91.99 %
5 Year Return
-98.81 %

Sonoma Pharmaceuticals Stock Fundamentals & Key Indicators

Check Sonoma Pharmaceuticals market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$6.0M

EPS (TTM)

-1.22

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-1.02

Industry PE ratio

-7.63

PEG Ratio

-0.01262526677055835

EBITDA

-1.6M

Revenue (TTM)

21.9M

Profit Margin

38.91%

Return On Equity TTM

-53.56%

Sonoma Pharmaceuticals Stock Valuation

Track how Sonoma Pharmaceuticals P/E has moved over time to understand its valuation trends.

Sonoma Pharmaceuticals in the last 5 years

  • Overview

  • Trends

Lowest (-4.18x)

June 30, 2022

Industry (-7.63x)

March 31, 2026

Today (-1.13x)

March 31, 2026

Highest (-0.58x)

March 31, 2024

LowHigh

Today’s Price to Earnings Ratio: -1.13x

Sonoma Pharmaceuticals vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Sonoma Pharmaceuticals with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Sonoma Pharmaceuticals image
Sonoma Pharmaceuticals
Buy$6.0M-98.81%-1.0238.91%0.00%
United Therapeutics image
United Therapeutics
Buy$20.3B143.7%15.6286.14%0.00%
Viatris image
Viatris
Buy$19.7B33.26%-48.3934.83%2.80%
Haleon PLC Sponsored ADR image
Haleon PLC Sponsored ADR
Buy$39.9BNA19.0165.57%1.36%
Zoetis image
Zoetis
Buy$30.1B-65.3%11.5670.87%2.92%
See all

Stock Returns calculator for Sonoma Pharmaceuticals Stock including INR - Dollar returns

The Sonoma Pharmaceuticals stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

Sonoma Pharmaceuticals investment value today

Current value as on today

₹33,968

Returns

-₹66,032

(-66.03%)

Returns from Sonoma Pharmaceuticals Stock

-₹68,564 (-68.56%)

Dollar Impact

₹2,532 (+2.53%)

Analyst Recommendation on Sonoma Pharmaceuticals Stock

Based on 7 analysts

BUY

85.71%

Buy

14.29%

Hold

0.00%

Sell

Based on 7 analysts, 85.71% of analysts recommend a 'BUY' rating for Sonoma Pharmaceuticals. Average target price of $12

Sonoma Pharmaceuticals Share Price Target

Get share price movements and forecasts by analysts on Sonoma Pharmaceuticals.

What analysts predicted

89.42%UPSIDE

Target Price

$12

Current Price

$1.27

Analyzed by

7 Analysts

Target

$12.00

Sonoma Pharmaceuticals target price $12, a slight upside of 89.42% compared to current price of $1.27. According to 7 analysts rating.

Indian Investors' Interest in Sonoma Pharmaceuticals Stock

Search interest for Sonoma Pharmaceuticals Stock has decreased by -78% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-78% versus previous 30 day period

Sonoma Pharmaceuticals Quarterly Profit & Loss

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
3
3
3
3
3
3
5
4
5
6
Gross Profit
1
1
1
1
1
1
2
1
2
2
Operating Income
0
-1
-1
0
-1
0
0
0
0
0
EBITDA
0
-1
-1
0
0
0
0
0
0
0
Interest Expense
-
-
-
-
-
-
-
-
-
-
Depreciation
0
0
0
0
0
0
0
0
0
-
Income Before Tax
0
-1
0
0
0
0
0
0
0
0
Income Tax Expense
0
0
0
0
0
0
0
0
0
-
Net Income
0
-1
-1
0
0
0
0
0
0
0
Net Profit Margin
46.53%
31.72%
38.51%
38.03%
35.63%
40.70%
37.83%
37.94%
39.22%
40.23%

Sonoma Pharmaceuticals Annual Profit & Loss

All numbers in Millions USD

Mar 2017
Mar 2018
Jun 2019
Jun 2020
Jun 2021
Jun 2022
Mar 2023
Mar 2024
Mar 2025
Mar 2026
Total Revenue
12
16
18
17
18
12
13
12
14
19
Gross Profit
5
7
8
8
6
3
4
4
5
7
Operating Income
-12
-14
-11
-7
-3
-5
-4
-4
-3
-2
EBITDA
-12
-13
-10
-3
-3
-5
-5
-4
-2
-2
Interest Expense
0
0
0
0
0
0
-
-
-
-
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-12
-14
-11
-3
-3
-5
-5
-5
-2
-3
Income Tax Expense
-4
0
0
0
0
0
0
0
0
0
Net Income
9
-14
-11
-3
-3
-5
-5
-4
-3
-3
Net Profit Margin
44.19%
43.88%
46.81%
45.30%
35.21%
31.62%
33.73%
37.26%
38.25%
37.97%

Sonoma Pharmaceuticals Quarterly Cash Flow

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
0
-1
-1
0
0
0
0
0
0
0
Operating Cash Flow
0
0
0
0
0
0
0
0
0
0
Investing Cash Flow
0
0
0
0
0
0
0
0
0
0
Financing Cash Flow
0
0
0
1
1
0
0
0
0
3
Change in Cash
1
0
0
1
1
1
0
0
0
2

Sonoma Pharmaceuticals Annual Cash Flow

All numbers in Millions USD

Mar 2017
Mar 2018
Jun 2019
Jun 2020
Jun 2021
Jun 2022
Mar 2023
Mar 2024
Mar 2025
Mar 2026
Net Income
9
-14
-11
-3
-3
-5
-5
-4
-3
-3
Operating Cash Flow
-8
-12
-11
-4
-3
-4
-6
-2
0
-3
Investing Cash Flow
18
0
0
3
0
0
0
0
0
0
Financing Cash Flow
0
5
5
1
3
7
2
1
3
0
Change in Cash
9
-7
-6
0
0
3
-3
0
2
-2

Mutual Funds that own Sonoma Pharmaceuticals Stock

Check out the Mutual Funds with significant holdings in Sonoma Pharmaceuticals.

Funds
Holdings
Shares Held
VANGUARD INDEX FUNDS
0.392341%
18787
Fidelity Concord Street Trust
0.309099%
14801

Global Institutional Holdings in Sonoma Pharmaceuticals

Funds
Holdings
VANGUARD INDEX FUNDS
0.39%
Vanguard
0.39%
Fidelity Concord Street Trust
0.31%

Insights on Sonoma Pharmaceuticals

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 3 quarters, 4.34M → 6.40M (in $), with an average increase of 17.5% per quarter

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 3 quarters, -819.0K → -330.0K (in $), with an average increase of 58.5% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, United Therapeutics Corporation Common Stock has given 85.9% return, outperforming this stock by 177.9%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Viatris Inc. Common Stock has given 87.3% return, outperforming this stock by 155.9%

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 3 years, SNOA stock has moved down by -92.0%

About Sonoma Pharmaceuticals

Sonoma Pharmaceuticals, Inc. specializes in the creation and distribution of stabilized hypochlorous acid (HOCl) products. These offerings address a diverse range of medical and health needs, including wound management, veterinary care, ocular hygiene, oral health, and various dermatological conditions. The company's market reach extends across the United States, Latin America, Europe, and other international territories. Its comprehensive product line features: Epicyn: an antimicrobial cleanser for facial use. Levicyn: a prescription HOCl-based treatment formulated to ease the burning, itching, and pain associated with numerous dermatological issues. Celacyn gel: a topical HOCl-based prescription product engineered to facilitate efficient healing and management of both new and old scars. SebuDerm: designed to soothe the burning, itching, redness, scaling, and discomfort linked to seborrhea and seborrheic dermatitis. Acuicyn: an HOCl-based solution for alleviating ocular itch and inflammation, while also maintaining cleanliness around the eyes. Microcyn: a topical HOCl product family aimed at accelerating wound healing by combating a wide spectrum of pathogens, including antibiotic-resistant strains that can impede natural recovery. MicrocynAH: an HOCl-based solution specifically for animals, providing relief for common conditions like hot spots, scratches, skin rashes, post-surgical sites, and irritated skin to support healing. Microdacyn60: an oral care solution for treating infections of the mouth and throat. MucoClyns: suitable for emergency use and safe for application on mucous membranes, cuts, abrasions, burns, and other body surfaces. Endocyn: a series of solutions for root canal irrigation. Pediacyn: a hydrogel designed for atopic dermatitis. Ocucyn: a cleanser for eyelids and eyelashes. Gramaderm: for the topical treatment of mild to moderate acne. Nanocyn: a hospital-grade disinfectant. Sinudox: for nasal irrigation purposes. Originally incorporated in 1999 as Oculus Innovative Sciences, Inc., the company officially rebranded to Sonoma Pharmaceuticals, Inc. in December 2016. Its headquarters are located in Woodstock, Georgia.
OrganisationSonoma Pharmaceuticals
Headquarters5445 Conestoga Court, Boulder, CO, 80301, US
IndustryDrug Manufacturers - Specialty & Generic
CEOAmy Trombly
E-voting on sharesClick here to vote

Key Management of Sonoma Pharmaceuticals

Name

Title

Ms. Amy M. Trombly Esq., J.D.

CEO, President & Director

Mr. Jerome J. Dvonch CPA

Chief Financial Officer

Mr. Arturo Angel

Senior Vice President of Regulatory, Quality & Product Development

FAQs

What is Sonoma Pharmaceuticals share price today?

Sonoma Pharmaceuticals share price today is $1.27 as on at the close of the market. Sonoma Pharmaceuticals share today touched a day high of $1.29 and a low of $1.24.

What is the 52 week high and 52 week low for Sonoma Pharmaceuticals share?

Sonoma Pharmaceuticals share touched a 52 week high of $4.60 on and a 52 week low of $0.85 on . Sonoma Pharmaceuticals stock price today i.e. is closed at $1.27,which is 72.39% down from its 52 week high and 49.39% up from its 52 week low.

What is Sonoma Pharmaceuticals's market capitalisation today?

Sonoma Pharmaceuticals market capitalisation is $0.00T as on .

How to invest in Sonoma Pharmaceuticals Stock (SNOA) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Sonoma Pharmaceuticals on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Sonoma Pharmaceuticals Shares that will get you 1.1811 shares as per Sonoma Pharmaceuticals share price of $1.27 per share as on September 26, 2026 at 8:45 am IST.

What is the minimum amount required to buy Sonoma Pharmaceuticals Stock (SNOA) from India?

Indian investors can start investing in Sonoma Pharmaceuticals (SNOA) shares with as little as ₹95.819999694824 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹958.20 in Sonoma Pharmaceuticals stock (as per the Rupee-Dollar exchange rate as on ). Based on Sonoma Pharmaceuticals share’s latest price of $1.27 as on September 26, 2026 at 8:45 am IST, you will get 7.8740 shares of Sonoma Pharmaceuticals. Learn more about fractional shares .

What are the returns that Sonoma Pharmaceuticals has given to Indian investors in the last 5 years?

Sonoma Pharmaceuticals stock has given -98.81% share price returns and 29.7% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?